Maria della Porta, OD
Optometrist · Bristol, CTNPI 1699781419
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 226 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,101, 4.9 times the $639 reported in 2019. Among optometrist clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 226 payments — averaging $43.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$2K
- Lumenis BE Inc$1K
- Sun Pharmaceutical Industries Inc.$775
- AbbVie$629
- Tarsus Pharmaceuticals, Inc.$594
- Dompe US, Inc.$522
- plus $4K from 22 others
What the payments were for
- Consulting fees$3003%
- Food & beverage$9,46697%
- Gifts$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 44 | $1,790 |
| Lumenis BE Inc | 1 | $1,007 |
| Sun Pharmaceutical Industries Inc. | 20 | $775 |
| AbbVie(2 entities) | 35 | $629 |
| Tarsus Pharmaceuticals, Inc. | 11 | $594 |
| Dompe US, Inc. | 11 | $522 |
| Johnson & Johnson Vision Care, Inc. | 6 | $502 |
| Alcon | 12 | $445 |
| Coopervision Inc. | 11 | $428 |
| Biotissue Holdings Inc. | 5 | $389 |
| Sight Sciences, Inc. | 8 | $370 |
| Novartis | 9 | $358 |
| Maculogix, Inc. | 2 | $347 |
| Kala Pharmaceuticals, Inc. | 10 | $276 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $205 |
| Harrow Eye, LLC | 12 | $193 |
| Oyster Point Pharma, Inc. | 5 | $165 |
| Eyevance Pharmaceuticals LLC | 5 | $156 |
| Glaukos Corporation | 1 | $140 |
| LKC Technologies, Inc. | 1 | $139 |
| Spark Therapeutics, Inc. | 1 | $125 |
| Rxsight Inc | 1 | $100 |
| Shire North American Group Inc | 2 | $41 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Lombart Brothers, Inc. | 2 | $25 |
| Quidel Corporation | 1 | $16 |
| Thea Pharma Inc. | 1 | $15 |
| ABB Con-cise Optical Group LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,804 in reported general payments places this provider in the 95th percentile of 574 optometrist providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 76 | $113,756 |
| LumiganBimatoprost | 80 | $47,575 |
| XiidraLifitegrast | 25 | $40,015 |
| MieboPerfluorohexyloctane/Pf | 26 | $19,821 |
| Cyclosporine | 41 | $18,630 |
| TyrvayaVarenicline Tartrate | 17 | $11,011 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $4,936 |
| Brimonidine Tartrate | 13 | $4,310 |
| Fluorometholone | 31 | $3,573 |
| Timolol Maleate | 38 | $3,265 |
| Loteprednol Etabonate | 14 | $2,676 |
| Travoprost | 12 | $2,237 |
| Latanoprost | 111 | $2,012 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 13 | $1,004 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 34 | $399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $629 | $161,330156 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $1,790 | $59,83651 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $165 | $11,01117 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $205 | $2,67614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 574 optometrist providers in Connecticut.
Other optometrist in Bristol
- Michelle MooreBristol$5K
- Joseph ThimonsFairfield$340K
- Inna LazarOld Greenwich$147K
- Jennifer StewartNew Canaan$91K
- Maria PribisStamford$78K
- Michael CooperWest Hartford$44K
- Joseph PavanoNew Britain$22K
- Susan JanikWest Hartford$20K
- Donald HigginsPlainville$18K
- Richard NowakEast Windsor$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.